NCT06571734View on ClinicalTrials.gov

XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

September 19, 2024

Primary Completion Date

July 1, 2028

Study Completion Date

July 1, 2029

Conditions
Metastatic LeiomyosarcomaUnresectable Leiomyosarcoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Echocardiography

Undergo ECHO

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

DRUG

Zanzalintinib

Given PO

Trial Locations (1)

60611

RECRUITING

Northwestern University, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER